Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitisProposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver…

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - Life Sciences British Columbia

Bausch Health will indirectly acquire DURECT Corporation, including a novel therapeutic molecule, larsucosterol.

Bausch Health to buy Durect for $63M upfront; Fulcrum’s Ph1b sickle cell data

Plus, news about Celcuity, NeOnc Technologies and Arvinas: Bausch Health to acquire Durect Corp. for $63M upfront: Bausch is buying the biopharma company to strengthen its hepatology business. In addition to ...